Physician profile
Daniel Marc Tuckerman
NPI 1164957478
$1,722.10
in general payments reported to CMS, 2019-2025
14 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2021: $130 · 2022: $235 · 2023: $543 · 2024: $395 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $255.02 | 2024 | Veklury |
| Pfizer INC. | $239.84 | 2021-2025 | |
| Abbvie INC. | $238.29 | 2021-2024 | Dalvance, Avycaz, Teflaro |
| Janssen Pharmaceuticals, INC | $231.27 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $161.08 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $147.68 | 2025 | Uptravi, Opsumit |
| Paratek Pharmaceuticals, INC. | $127.20 | 2022-2023 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $93.28 | 2022-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $62.34 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $52.46 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $34.47 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $30.46 | 2023 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $26.67 | 2022 | |
| Edwards Lifesciences Corporation | $22.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.